The Innovative Cardiovascular Health Program

 

This program purpose is referencing unequal socioeconomic conditions and unfair opportunity structures have long existed and contribute to poor health outcomes in minority and ethnic populations and geographically and economically disadvantaged communities. Poverty, inferior housing and health care, and other debilitating social conditions are endemic to some communities, including Non-Hispanic Black (NHB), Hispanic, and Native American communities. Research highlights the high prevalence of cardiovascular disease (CVD), including hypertension, high cholesterol, and stroke in these groups. CVD is the leading cause of death in the US and stroke is the 5th leading cause with an estimated 1 in 9 health care dollars spent treating CVD. Despite significant decreases in CVD rates in the last 20 years, NHB continue to have higher CVD mortality rates than Non-Hispanic Whites (NHW). In 2019, NHB women and men younger than 65 were 2.0 and 1.3 times more likely to experience premature death from CVD than their NHW counterparts. In 2020, NHB had the highest heart disease mortality rates at 228.6 per 100,000 and stroke at 56.8 per 100,000. Uncontrolled hypertension is the primary contributor to morbidity and mortality rate disparities in CVD between NHB and other racial and ethnic groups. In 2019, NHB had more than double the age-adjusted death rates (56.7) attributable primarily to hypertension compared to NHW (25.7). Of the 1 in 2 US adults with hypertension, only 26.1% have controlled blood pressure. By age 55, the cumulative incidence of hypertension reaches almost 76% in NHB men and women, compared to 54.5% and 40.0% among NHW men and women, respectively. Moreover, NHB had a 1.5 to 2 times higher risk for hypertension after adjustment for other factors, regardless of baseline blood pressure. Among NHB adults who did not report a hypertension diagnosis, a larger proportion (28%) were unaware of hypertension (BP ?140/90 mm Hg) compared to NHW adults (16%). Despite the similar rate of hypertension treatment, only one-third of NHB adults had their blood pressure controlled, in contrast to 45.0% of NHW adults. These data clearly indicate that NHB bear the greatest burden of CVD among US adults. The outcomes are as stark in other CVD-related illnesses. Although the prevalence of high cholesterol in NHB is comparable to or lower than in NHW, racial-ethnic disparities occur at every level of diagnosis and management. The disparities present in low screening rates, fewer prescriptions, and medication adherence. Unsatisfactory control of high cholesterol among NHB stems from the same adverse social conditions that hinder the control of hypertension. Interventions must include an understanding of individual and community factors that influence a healthy diet, losing weight, being physically active, and medication adherence to address the disparities and inequities. There is a need for equity-focused health system interventions to prevent, detect, control, and manage hypertension and high cholesterol. Building on lessons from the previous work, this program focuses on comprehensive efforts to identify and respond to health care disparities and improve CVD-related outcomes, specifically for those with hypertension and high cholesterol. Populations of focus for this program are adults aged 18 and older with a hypertension crude prevalence of 53% or higher, as shown by data specifically at the census tract level. Emphasis should be placed on achieving impact and reach across geographic locations where disparate populations can benefit from the strategies included in this program.

Active 93.435 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Section 301(a) of the Public Health Service Act [42] U.S.C. Section 241(a) Title IV Section 4002 of the Affordable Care Action, Prevention and Public Health Fund State or local health departments or their Bona Fide Agents (includes the District of Columbia) Eligibility will be limited to state and local/city/county governments with a population of 900,000 or more with the greatest potential to reach and impact large numbers of high risk/high burden populations, or their bona fide agents. Consortia of smaller local/city/county health departments may collaborate to submit one application that, collectively, represents a population of 900,000 or more. Beneficiaries of this program include: State, Local, Individual/Family, Minority Group, Anyone/General Public, Black American, American Indian, Spanish Origin, Oriental, Other Nonwhite, Women, Handicapped, Physically Afflicted, Senior Citizen, Rural Any required credentials and/or documentation will be identified in the specific Notice of Funding Opportunity (NOFO) for this Assistance Listing. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. Refer to the NOFO posted on grants.gov for additional information. This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any. Check Grants.gov for any relevant NOFO information regarding processes for applying for assistance. From 120 to 180 days. Not applicable. From 120 to 180 days. Project period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government. Applications will be evaluated on the review criteria described in the Notices of Funding Opportunity (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC. Funds for this program are to be used to design, test, and evaluate novel approaches to addressing a set of evidence based strategies aimed at reducing risks, complications, and/or barriers to prevention and control of diabetes and cardiovascular disease among high-burden populations. Performance Reports: Annual Federal Financial Reports (FFR) and performance/progress reports are required. Final FFRs and performance reports are required. Other reporting may be required and will be outlined in the NOFO or the Notice of Award. CDC requires awardees to meet all record retention requirements defined in the notice of award, the funding opportunity, the HHS grants policy statement, and 45 CFR Part 75. In accordance with 2 CFR ?200, as codified in 45 CFR ?75, there is a 3-year record retention requirement; records shall be retained beyond the 3-year period if final audit has not been done or findings resolved. Property records must be retained in accordance with HHS Grants Policy Statement requirements. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient. Notice of Award None/Not specified. Sheryl Heard
4770 Buford Highway, NE
Atlanta, GA 30341 US
slh3@cdc.gov
Phone: 7704882855 http://www.cdc.gov 75-0943-0-1-550 (Cooperative Agreements) FY 22$35,983,121.00; FY 23 est $21,150,000.00; FY 24 est $21,150,000.00; FY 21$41,528,477.00; FY 20$41,528,477.00; FY 19$41,528,477.00; FY 18$39,928,477.00; FY 17$0.00; - Awards for this new program are expected to range from $1,000,000 to $3,500,000. Awards will be based on activities proposed by the applicant, the burden of disease of diabetes and heart disease and stroke, and the recipient's potential reach and effect outcomes for large numbers of adults. Not applicable. Not applicable.